Access Bio, Inc.

KOSDAQ:A950130 Stock Report

Market Cap: ₩173.5b

Access Bio Past Earnings Performance

Past criteria checks 0/6

Access Bio has been growing earnings at an average annual rate of 3.4%, while the Medical Equipment industry saw earnings growing at 18.7% annually. Revenues have been growing at an average rate of 16.1% per year.

Key information

3.4%

Earnings growth rate

3.8%

EPS growth rate

Medical Equipment Industry Growth22.7%
Revenue growth rate16.1%
Return on equity-2.5%
Net Margin-11.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem

Mar 26
Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem

Recent updates

Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares

Nov 13
Access Bio, Inc.'s (KOSDAQ:950130) Prospects Need A Boost To Lift Shares

Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking

Aug 07
Optimistic Investors Push Access Bio, Inc. (KOSDAQ:950130) Shares Up 38% But Growth Is Lacking

Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem

Mar 26
Access Bio's (KOSDAQ:950130) Earnings Are Weaker Than They Seem

Is Access Bio (KOSDAQ:950130) A Risky Investment?

Mar 25
Is Access Bio (KOSDAQ:950130) A Risky Investment?

If You Had Bought Access Bio (KOSDAQ:950130) Shares A Year Ago You'd Have Earned 740% Returns

Feb 18
If You Had Bought Access Bio (KOSDAQ:950130) Shares A Year Ago You'd Have Earned 740% Returns

Revenue & Expenses Breakdown

How Access Bio makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A950130 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24118,855-13,30442,99610,846
30 Jun 24100,208-15,71142,07211,624
31 Mar 24141,282-42,21858,84014,292
31 Dec 23348,643-3,173130,25716,081
30 Sep 23362,4496,978152,72717,350
30 Jun 23371,791-2,032162,33015,464
31 Mar 23452,09499,507166,7139,878
31 Dec 221,033,863346,670342,4717,316
30 Sep 221,205,808418,017374,5506,125
30 Jun 221,234,194452,910365,1525,739
31 Mar 221,103,446356,212373,2155,277
31 Dec 21505,112189,690130,3704,894
30 Sep 21374,187168,03476,1864,371
30 Jun 21344,042151,25670,5514,278
31 Mar 21338,051171,59333,0314,284
31 Dec 20121,79748,27218,9144,006
30 Sep 2040,472-23013,8113,188
30 Jun 2042,118-14,56719,0922,950
31 Mar 2042,755-17,21818,9082,536
31 Dec 1943,059-17,58818,2832,200
30 Sep 1941,675-18,98418,5462,394
30 Jun 1938,944-7,13413,1882,326
31 Mar 1939,874-5,22614,8772,646
31 Dec 1840,239-4,24115,5452,934
30 Sep 1840,283-4,47714,6062,458
30 Jun 1840,535-4,94115,1892,564
31 Mar 1834,392-5,46013,1412,370
31 Dec 1729,465-6,48612,7301,942
30 Sep 1727,348-4,51112,8722,041
30 Jun 1725,438-3,40812,2881,745
31 Mar 1729,884-1,64312,5791,498
31 Dec 1632,48630412,4181,510
30 Sep 1633,6891,79411,7821,351
30 Jun 1632,2112,45711,0581,311
31 Mar 1633,0622,01210,4621,090
31 Dec 1535,5831,2659,935971
30 Sep 1530,4926209,682967
30 Jun 1532,6692439,288896
31 Mar 1532,7341,1999,532828
31 Dec 1432,3052,43212,106815
30 Sep 1442,4895,30712,985797
30 Jun 1445,1267,61113,493655
31 Mar 1446,8748,10113,494566
31 Dec 1345,8407,83811,838415

Quality Earnings: A950130 is currently unprofitable.

Growing Profit Margin: A950130 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A950130 is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.

Accelerating Growth: Unable to compare A950130's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A950130 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-13.3%).

Return on Equity

High ROE: A950130 has a negative Return on Equity (-2.47%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:07
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Access Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jongsun ParkEugene Investment & Securities Co Ltd.
Gwang Sik ParkKyobo Securities Co., Ltd
Kyung-Churl NohSK Securities Co., Ltd.